Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Expansion of Community Health Programs by Novartis to Tackle Global Health Disparities
Novartis’ ambitious scale-up of community health programs aims to close critical gaps in cardiovascular and cancer care. Announced on April 9, 2026, the initiative will expand these community health programs from 11 to more than 30 countries by 2030, including five major U.S. cities, with a stron...
Antimicrobial Resistance Art: Bridging Science and Health Through Visual Storytelling
Antimicrobial resistance art is powerfully demonstrated in the illustrated album Sketching Antimicrobial Resistance: Thirty Stories, One Health, published in November 2025 by the EU-JAMRAI 2 initiative. The publication brings together 30 original artworks from artists across 30 European ...
Differentiated Visceral Fat Reduction in Early Trials of WVE-007
New clinical evidence shows meaningful visceral fat reduction with a single dose of an investigational therapy. A single 240 mg dose of WVE-007, an investigational INHBE GalNAc-siRNA (SpiNA design), produced continued placebo-adjusted reductions in visceral fat mass (−14.3%; p<0.05) and total ...